Immune cells take on nerve tumors: new trial launches
NCT ID NCT04085159
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged 1 year and older whose tumors have specific markers. The main goal is to check for side effects, with a secondary focus on whether the cells can be successfully made and work against the tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Antigen-specific T cells (CAR-T and CTL) and dendritic cell vaccine
- What this could lead to
- If successful, this could lead to a new treatment option that helps control tumors in people with neurofibromatosis or schwannomatosis.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. There may be side effects from the cell therapy, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?